Dry Age-Related Macular Degeneration Clinical Trial Pipeline Highlights 2019 – Forecast to 2024 by Clinical Stage, Drug Mechanism Classes, & Companies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Dry Age-Related Macular Degeneration Clinical Trial Pipeline Highlights
– 2019” report has been added to ResearchAndMarkets.com’s
offering.

Dry Age-Related Macular Degeneration Pipeline Highlights – 2019,
provides most up-to-date information on key pipeline products in the
global Dry Age-Related Macular Degeneration market.

It covers emerging therapies for Dry Age-Related Macular Degeneration in
active clinical development stages including early and late stage
clinical trials. The pipeline data presented in this report helps
executives for tracking competition, identifying partners, evaluating
opportunities, formulating business development strategies, and
executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Dry Age-Related Macular Degeneration pipeline
products by clinical trial stages including both early and late stage
development – phase 3 clinical trials, phase 2 clinical trials, phase 1
clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Dry Age-Related Macular Degeneration pipeline
products by their dominant mechanism of action/drug class. This helps
executives categorize products based on their drug class and also assess
the strengths and weaknesses of compounds.

Company:

The report provides Dry Age-Related Macular Degeneration pipeline
products by the company.

Short-term Launch Highlights:

Find out which Dry Age-Related Macular Degeneration pipeline products
will be launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Dry Age-Related Macular Degeneration Pipeline by Stages

2. Dry Age-Related Macular Degeneration Phase 3 Clinical Trial Insights

3. Dry Age-Related Macular Degeneration Phase 2 Clinical Trial Insights

4. Dry Age-Related Macular Degeneration Phase 1 Clinical Trial Insights

5. Dry Age-Related Macular Degeneration Preclinical Research Insights

6. Dry Age-Related Macular Degeneration Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/91py2k

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Optical
Disorders Drugs